Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.74 EUR
Change Today -0.016 / -2.13%
Volume 58.2K
VSC On Other Exchanges
As of 2:01 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

4sc ag (VSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/14 - €1.58
52 Week Low
02/26/15 - €0.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 4SC AG (VSC)

Related News

No related news articles were found.

4sc ag (VSC) Related Businessweek News

No Related Businessweek News Found

4sc ag (VSC) Details

4SC AG researches and develops small-molecule drugs for the treatment of cancer and autoimmune diseases. The company operates through two segments, Development and Discovery & Collaborative Business. Its product portfolio in the area of autoimmune includes Vidofludimus, an orally administered small-molecule drug, which is in Phase II b clinical trial for the treatment of crohn’s diseases. The company’s product portfolio in the area of oncology comprises Resminostat, an oral pan-histone-deacetylase inhibitor, which is in Phase II and Phase I clinical trials for the treatment of liver cancer, hodgkin lymphoma, colorectal cancer, non-small-cell lung cancer, and solid tumors; 4SC-202, an epigenetic anti-cancer compound that is in Phase I clinical trials for the treatment of hematologic tumors; and 4SC-205, an anti-cancer compound, which is in Phase I clinical trials for the treatment of solid tumors. It also conducts research programs in the areas of cancer immunotherapy, cancer stem cells, epigenetics, cytokine modulation, and ion channel blockers for the treatment of autoimmune, inflammatory eye, and oncology diseases. The company was founded in 1997 and is headquartered in Martinsried, Germany.

55 Employees
Last Reported Date: 11/7/14
Founded in 1997

4sc ag (VSC) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: €278.0K
Co-Founder, Chief Scientific Officer, Chief D...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2013.

4sc ag (VSC) Key Developments

4SC AG Announces Executive Changes

4SC AG announced that Prof. Dr. Helga Rubsamen-Schaeff and Joerg von Petrikowsky have been appointed as new members of its Supervisory Board. Since 2006, Prof. Dr. Rubsamen-Schaeff has acted as Managing Director and CEO of AiCuris GmbH, a German biopharma company founded by her. In this capacity, she was responsible, among other things, for securing a licensing deal with US pharmaceutical company Merck with a total value of up to EUR 442 million plus royalties. Joerg von Petrikowsky has more than 30 years of experience as an auditor and tax adviser focusing in particular on the auditing and advising of international pharmaceutical, medical technology and biotechnology companies. On the Supervisory Board of 4SC, Mr. von Petrikowsky will act as Chairman of the Audit Committee and as the independent financial expert. Both terms of office will initially run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for the financial year 2014. Prof. Dr. Rubsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kuhn who recently stepped down.

4SC AG Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

4SC AG Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

4SC AG Reports Positive Topline Data from Clinical Phase I trial with 4SC-205 in Cancer Patients Using Novel Continuous Dosing Scheme

4SC AG announced positive top line data from the clinical Phase I AEGIS trial with the anti-cancer compound 4SC-205 in cancer patients. 4SC-205 inhibits specifically the human kinesin spindle protein Eg5 which has been shown to play a crucial role in cell division and, therefore, in tumour growth. To 4SC's knowledge, 4SC-205 is the only orally available Eg5 inhibitor in clinical development worldwide. Conducted at two trial centres in Germany, the open-label AEGIS dose-finding study for the first time investigated the innovative 4SC-205 compound in 59 patients with advanced solid tumours. This involved the testing of two separate dosing schemes. As previously reported, the first part of the study, treating 46 patients with 4SC-205 in a conventional dosing scheme (with single, larger doses and longer breaks between treatment days), had delivered promising initial results for pharmacokinetics, the tolerability profile and biomarkers. The second part of the study has been completed now. In this study amendment, 4SC-205 was evaluated in 13 patients with advanced solid tumours using a metronomic, or continuous, dosing scheme. In this regimen, patients received the compound, in smaller single doses, daily and continuously (= no breaks between treatment days). This regimen aims to achieve and maintain permanent therapeutically active levels of the drug in patients while keeping side effects tolerable at the same time. The oral availability of 4SC-205 and its mechanism of action as a potential cell division inhibitor make this dosing scheme promising from a scientific and clinical perspective. To the knowledge of the company, 4SC-205 is the first Eg5 inhibitor that has been clinically evaluated in patients in this dosing scheme to date. All primary objectives of the study amendment have been achieved. Alongside very good linear pharmacokinetic parameters, a comprehensive safety and tolerability profile was established for 4SC-205. The continuous daily dosage of 20 mg of the compound showed promising initial signs of efficacy and is recommended as the dosage regimen for potential Phase II development. Currently one patient whose previously strongly pronounced and highly aggressive cancer has been stabilized for eight months now is still continuing study treatment. 4SC will now proceed to discuss the results with external clinical key opinion leaders and potential partners, so as to assess further development options for 4SC-205 - such as a clinical Phase II trial. In the metronomic dosing scheme investigated in the study amendment, the patients were continuously treated (i.e. without breaks between treatment days) in three separate dosage groups that received daily doses of 10 mg, 20 mg or 30 mg of 4SC-205 respectively. The main study objective was to identify the maximum tolerated dose for the treatment and potential dose-limiting toxicities (DLTs). The main study phase to be completed by all patients according to the study protocol was six weeks, i.e. two continuous treatment cycles, each of 21 days. After completion of this main phase, the follow-up phase then allowed patients benefiting from the treatment - in the form of a stabilization of their previously progressive cancers - to continue the treatment. In these patients, the MTD was established as a daily dose of continuous 20 mg. The DLT was determined at a continuous daily dose of 30 mg of 4SC-205. Primary side effects at DLT level were neutropenia (level 3-4). Moreover, 4SC-205 showed a very good pharmacokinetic profile with a dose proportional increase of exposure and an elimination half-life of about ten hours providing the basis for effective dosing schedules. 4SC recommends the daily dose of 20 mg in the metronomic treatment regimen as a well tolerable and potentially effective dose (Recommended Phase 2 Dose, RP2D) for a possible Phase II development of the compound. Compared with the other doses examined in this trial, the six patients in this 20 mg daily metronomic group exhibited markedly superior indications for treatment efficacy, both in terms of a higher stabilization rate and a longer time on study. Accordingly, in a total of 50% of patients receiving this metronomic dose of 20 mg per day, the previously progressive cancer disease could be stabilized beyond the study's main phase into the follow-up phase. In comparison, the average stabilization rate of all patients was 30% in the metronomic dosing scheme and 20% in the conventional dosing scheme. The median time on study of the patients receiving the daily metronomic dose of 20 mg was 128 days. In comparison, the median time on study for all patients in the metronomic dosing scheme was 44 days and 40.5 days for all patients under the conventional dosing scheme. Currently one patient, whose previously strongly pronounced and highly aggressive cancer disease (malignant melanoma with pulmonary metastases) has been stabilized for eight months under the continuous daily dose of 20 mg 4SC-205, is still continuing study treatment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSC:GR €0.74 EUR -0.016

VSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 4SC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at